capabilities

Capabilities

We utilize our resources, codify routines and procedures, embedding capabilities that go beyond general business practices, while simultaneously developing the skills of our talented employees. Commercial League is far ahead in the management of financial risk as compared to our major peers in the region.

Over the years, Commercial League has been recognized for its superior distribution and logistics capacity, IT capabilities as well as brand building expertise. This has an important influence on the quantum of its major contract sales such as state tenders and financial performance. The fact that Commercial League has been so successful in the recent past is a good indication that it would be successful in the future, particularly in the manufacture and market entry of new biotech and personalized medicines.

As the largest company of its type in Bulgaria, Commercial League follows the industry’s mission through strong reform advocacy and public relations campaigns as well as popular public events (http://comleague.com/files/new/patriotizam_i_rodoliubie.pdf). Our flexibility and wide reach make us the most advanced and most often chosen strategic partner in confidential market research and intelligence as well as in the field of patent protected drug marketing across Central and Eastern Europe (http://comleague.com/files/new/success_stories.pdf).

Commercial League holds senior and very distinctive competencies and expertise, while outperforming competitors through:

  • Superior efficiency
  • High quality
  • Best-in-class innovation
  • Modern customer service and responsiveness
  • Speed and flexibility to changing conditions
  • Insightful and irresistible advocacy and lobbying capacity
  • Unrivaled corporate performance culture and goal orientation

For patients and consumers

Through its unmatched marketing strategy and know-how, Commercial League has introduced to Bulgarian patients a number of novel treatments for hypertension, diabetes, COPD, CNS disorders, multiple sclerosis, psoriasis, pulmonary hypertension, hyperphosphatemia in patients with end-stage renal failure, rheumatoid arthritis, and many more in mass and unmet orphan diseases.